Drug intelligence / Profile preview

AVC-S-103

Development stage: Preclinical
Lead developer: Avidicure
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AVC-S-103 is an antibody-drug conjugate (ADC) being developed by Avidicure for the treatment of HER2-positive malignancies, including breast and gastric cancers. The drug consists of a monoclonal antibody targeting the Human Epidermal Growth Factor Receptor 2 (HER2) conjugated to a cytotoxic payload. By binding to HER2-expressing tumor cells, AVC-S-103 is internalized, allowing for the targeted delivery and release of its cytotoxic agent to induce cell death while minimizing systemic toxicity. As of late 2024/early 2025, the program is in the IND-enabling stage of development.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on AVC-S-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVC-S-103.

Explore the full profile